Dr. Reddy’s Lab Shares Rise: Why DRREDDY Stock is Moving Today | 29 September 2026

NSE: DRREDDY · 29 September 2026 · Dated market coverage

Price
₹1,251.90
Change
+2.53%
High / Low
₹1,251.90 / ₹1,230.00
Prev. Close
₹1,221.00
Volume
5,154,261
Price as of
29 Sep 2026 • 03:15 PM IST
Key Takeaways
  • The stock is +2.53% at ₹1,251.90.
  • Likely reason:Strong volume-backed momentum and sector outperformance
  • Approximate traded value is₹645.26 crore.
  • It is -11.52% from its 52-week high and +13.71% from its 52-week low.
  • The stock is being compared withNifty Pharmaalongside the Nifty 50.

Why Is Dr. Reddy S Laboratories Share Price Rising Today?

Latest NSE EOD report: 2026-09-29. Today’s Volume: 5,154,261; 5-Day Avg. Volume: 2,479,893; 20-Day Avg. Volume: 1,636,892; Volume vs 20-Day Avg.: 3.15x; Delivery Quantity: 2,450,987; Delivery %: 45.84%; Number of Trades: 116,376.

Dr. Reddy’s Laboratories shares advanced during the session, trading near the upper end of the day’s range. The stock opened at ₹1,243.60 and touched a high of ₹1,251.90 before settling at ₹1,251.90, reflecting a gain of 2.53% over the previous close of ₹1,221.00. Trading volume was markedly robust, standing at over 2.08 times its 5-day average and more than 3.15 times its 20-day average, signaling elevated market participation.

The broader market sentiment was slightly negative, with the Nifty index slipping 0.28%. However, Dr. Reddy’s outperformed both the broader market and its sector benchmark, Nifty Pharma, which posted a modest gain of 0.64%. The stock’s positive momentum builds on a steady short-term recovery, adding to a 3.38% return over the past five sessions and a 6.91% gain over the last 20 trading days.

While the upward price movement coincides with ongoing operational updates—such as its recent exclusive distribution agreement with Takeda Biopharmaceuticals for Qdenga in India—no single fresh corporate catalyst was announced today. Consequently, the price action reflects a continuation of recent positive momentum supported by strong delivery volumes and sector-relative strength rather than a direct, newly disclosed corporate trigger.

Likely Reason for Today’s Move

low confidence

Strong volume-backed momentum and sector outperformance
The stock moved up 2.53% on heavy volume that was more than triple its 20-day average, outperforming a declining Nifty benchmark and gaining relative strength. Because no major new catalyst was released today, the move is best interpreted as continuation of recent positive momentum backed by strong market participation.
  • Daily price gain of 2.53% with the stock closing near the day’s high of ₹1,251.90
  • Volume surging to 3.15x its 20-day average
  • Outperformance against a weak Nifty index (-0.28%)

Ownership & Transaction Activity

Historical Insider Activity
Patrick AghanianInsider / disclosed person
TransactionBuy
Quantity3,675 shares
Trade date26 March 2026
Tricia WetzelInsider / disclosed person
TransactionBuy
Quantity4,275 shares
Trade date9 December 2025
Source: NSE transaction disclosures.

WittyTrades Data Insight

Price Position:The stock is near the upper end of the day’s trading range.

Move From Open:+0.67%.

Intraday Range:1.79% of the previous close.

5-Day Performance:+3.38%; 20-Day Performance:+6.91%.

Latest Company Developments

Exclusive Distribution Agreement for Qdenga
18-Sep-2026
Dr. Reddy’s Laboratories entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga in the private market in India. The partnership leverages Dr. Reddy’s established commercial footprint to expand access to the offering. This arrangement forms part of the company’s ongoing efforts to strengthen its domestic portfolio through strategic tie-ups.
Why it matters:It expands the company’s specialty product footprint in the private Indian market, though it serves as background business context rather than the direct cause of today’s share price movement.

Exchange Clarification on Media Report
18-Sep-2026
The stock exchanges sought clarification from Dr. Reddy’s Laboratories regarding a media report concerning a voluntary license for Gilead’s HIV prevention drug. The company provided its response to the exchange in line with disclosure norms. Such verification steps are standard administrative procedures that help maintain market transparency while awaiting official confirmations.
Why it matters:It addresses market queries regarding speculative media reports, though regulatory clarification requests by themselves do not confirm operational or financial impacts.

What Should Traders and Investors Watch Next?

  • Upcoming financial results for the quarter ending September 30, 2026, scheduled for October 23, 2026
  • Execution progress on recent distribution partnerships such as the Takeda Qdenga agreement
  • Regulatory updates regarding pending product approvals and exchange clarifications

Catalyst note:No single confirmed corporate catalyst drove today’s move; the advance reflects strong volume-backed momentum and outperformance against broader market weakness.

Frequently Asked Questions

What is the likely reason for today’s move?

The stock moved up 2.53% on heavy volume that was more than triple its 20-day average, outperforming a declining Nifty benchmark and gaining relative strength. Because no major new catalyst was released today, the move is best interpreted as continuation of recent positive momentum backed by strong market participation.

Is trading volume elevated?

Today’s volume is 5,154,261. The latest 20-day average available is 1,636,892, equivalent to about 3.15x of the recent average.

Before acting on this stock

Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review theWittyTrades subscription plans and research segments.

Article by:WittyTrades Research Desk

Disclaimer:Investments in securities markets are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, membership of a supervisory body and certification from NISM do not guarantee performance of the intermediary or provide any assurance of returns to investors. This article is intended for informational and educational purposes and should not be treated as personalised investment advice or a recommendation to buy, sell or hold any security. Market data may be delayed and readers should independently verify current prices and disclosures before taking investment decisions.

Other Dated Coverage

More Dr. Reddy S Laboratories news and dated analysis →

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top